Microvascular Research (MVR) is an international journal dedicated to the dissemination of fundamental information related to the microvascular field.

Submission of Manuscripts

It is a condition of publication that all manuscripts must be written in clear and grammatical English and be submitted to the Microvascular Research Web site at http://ees.elsevier.com/mvr. Minimal exceptions will be allowed. If you are unable to provide an electronic version of your paper, please contact the Editorial Office prior to submission (e-mail: mvr@elsevier.com; telephone; (619) 699-6275; fax: (619) 699-6211).

There are no submission fees or page charges. A letter outlining the basic findings of the paper and their significance should accompany each manuscript. To facilitate the publication of manuscripts, especially those papers based upon a new, theoretical concept, the Editors invite each contributor to submit the names of at least three scientists who could review the submitted manuscript.

Manuscripts are accepted for review with the understanding that no substantial portion of the study has been published or is under consideration for publication elsewhere and that its submission for publication has been approved by all the authors and by the institution where the work was carried out. Manuscripts that do not meet the general criteria or standards for publication in Microvascular Research will be immediately returned to the authors, without detailed review.

Copyright and permissions. Upon acceptance of an article, authors will be asked to sign a “Journal Publishing Agreement” (for more information on this and copyright, see http://www.elsevier.com/copyright). Acceptance of this agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a “Journal Publishing Agreement” form or a link to the online version of this agreement.

If material from other copyrighted works is included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: contact Elsevier Global Rights Department, P.O. Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.com.

US National Institutes of Health (NIH) voluntary posting (" Public Access") policy

Elsevier facilitates author response to the NIH voluntary posting request (referred to as the NIH "Public Access Policy"; see http://www.nih.gov/about/publicaccess/index.htm) by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author, 12 months after formal publication. Upon notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com) that your work has received NIH funding and that you intend to respond to the NIH policy request, along with your NIH award number to facilitate processing. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version of your manuscript that will include peer-review comments, for posting 12 months after formal publication. This will ensure that you will have responded fully to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed Central, and any such posting is prohibited.

When human subjects are used, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and written consent of each subject, with the approval of the appropriate local ethics committee, and in compliance with national legislation and the Code of Ethical Principles for Medical Research Involving Human Subjects of the World Medical Association (Declaration of Helsinki) http://www.wma.net/e/policy/b3.htm.
When experimental animals are used, the materials and methods section must clearly indicate that adequate measures were taken to minimise pain or discomfort, and that the experiments were conducted in accordance with international standards on animal welfare as well as being compliant with local and national regulations. Studies are expected to be compliant with minimal standards as defined by the European Communities Council Directive of 24 November 1986 (86/609/EEC) http://europa.eu.int/comm/food/fs/aw/aw_legislation/scientific/86-609-eec_en.pdf and the National Institutes of Health Guide for the Care and Use of Laboratory Animals http://www.nap.edu/readingroom/books/labrats/. Full details of any anaesthetic or analgesic dose and treatment must be given.
All manuscripts are expected to comply with contemporary standards of ethical practice in scientific publication, regarding such matters as study design and ethical approval, data probity and fabrication, authorship, declaration of conflict of interest, plagiarism and redundant publication.

Types of Articles

In addition to regular articles, MVR publishes the following:

Brief Communications. Preliminary reports will be reviewed for prompt publication; however, the comments must be restricted to no more than six typewritten pages, including references, tables, and illustrations. No abstract should be included.

Technical Reports. Please contact the Editor-In-Chief before submission.

Letter to the Editor. Letters to the Editor may consist of either of two types of correspondence: (1) a question or challenge to an article published recently in the journal or (2) a brief communication describing a preliminary research report or a review. Letters to the Editor should be limited to no more than three double-spaced typewritten pages and a maximum of five references.

Authors in Japan kindly note that, upon request, Elsevier Japan will provide a list of people who can check and improve the English of an article before submission. Contact our Tokyo office: Elsevier , 4F Higashi-Azabu, 1 Chome Bldg., 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; tel.: +81-3-5561-5032; fax: +81-3-5561-5045; e-mail:jp.info@elsevier.com.

Preparation of Manuscripts

Manuscripts should be double-spaced throughout. Pages should be numbered consecutively and organized as follows:

The Title Page (p. 1) should contain the article title, authors' names and complete affiliations, footnotes to the title, and the address for manuscript correspondence (including e-mail address and telephone and fax numbers). The title of the paper should be brief; no longer than 100 characters in length, and should capture and communicate the key message of your research to a broader audience. To aid this, abbreviations, unless familiar to a broad audience, should be avoided.

The Abstract (p. 2) must be a single paragraph that summarizes the main findings of the paper in less than 225 words. After the abstract a list of up to 10 keywords that will be useful for indexing or searching should be included.

The Introduction should be as concise as possible, without subheadings.

Materials and methods should be sufficiently detailed to enable the experiments to be reproduced.

Results and Discussion may be organized into subheadings.

Acknowledgments should be brief and should precede the references.

The References should be alphabetized by the first author's last name. References should be cited in the text by name and date. Cite papers with three or more authors using the first author's last name and "et al." Use the most rrecent edition of the Chemical Abstracts Service Source Index for abbreviations of journal titles.

Holleran, E.A., Karki, S., Holzbaur, E.L.F., 1998. The role of the dynactin complex in intracellular motility. In: Jeon, K.W. (Ed.), International Review of Cytology. Academic Press, San Diego, Vol. 182, pp. 69-109.

Patel, S., Pittman, R.N., 2002. Impact of microscope numerical aperture on microspectrophotometric measurements of hemoglobin in microvessels. Microvasc. Res. 64, 198-206.

Tsuchida, E. (Ed.), 1998. Blood Substitutes--Present and Future Perspectives. Elsevier, Amsterdam.

Only articles that have been published or are in press should be included in the references. Unpublished results or personal communications should be cited as such in the text.

Figures. Number figures consecutively with Arabic numerals. Please refer to http://www.elsevier.com/artworkinstructions for guidelines for the preparation of electronic artwork files.

Color figures

If together with your accepted article, you submit usable colour figures, then Elsevier will ensure, at no additional charge, that these figures will appear in colour on the Web (e.g., ScienceDirect and other sites) regardless of whether these illustrations are reproduced in colour in the printed version. For colour reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions [Please note: Because of technical complications that can arise in converting colour figures to “grey scale” (for the printed version should you not opt for colour in print), please submit in addition usable black-and-white files corresponding to all the colour illustrations].

Authors should note that a request to revert from full colour to colour only in the electronic publication at the stage of typesetting and proof correction, will require separate editorial agreement, with possible re-review if necessary, and may significantly delay publication of your manuscript.

Tables should be numbered consecutively with Arabic numerals in order of appearance in the text. Type each table double-spaced on a separate page with a short descriptive title typed directly above and with essential footnotes below.

Supplementary material:

Electronic supplementary material is now accepted to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more.Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our Corporate Website at http://www.elsevier.com/authors.

Proofs

PDF proofs will be e-mailed to the corresponding author. To avoid delay in publication, only necessary changes should be made, and corrections should be returned promptly. Authors will be charged for alterations that exceed 10% of the total cost of composition.

Offprints:

The corresponding author, at no cost, will be provided with a pdf offprint. Should they wish, they may opt to receive 50 paper offprints instead.

Author enquiries:

For enquiries relating to the submission of articles (including electronic submission where available) please visit this journal's EES page. You can track accepted articles at http://www.elsevier.com/trackarticle and set up e-mail alerts to inform you of when an article's status has changed, as well as copyright information, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication

Disclaimer:

Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinion or statement appears in this journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the sole responsibility of the contributor or advertiser concerned. Accordingly, the publishers, the editorial board and editors and their respective employees, officers and agents accept no responsibility or liability whatsoever for the consequences of any inaccurate or misleading data, opinion or statement.